23 patents
Utility
Alpha-amino Esters of Hydroxypropylthiazolidine Carboxamide Derivative and Salt Form, Crystal Polymorph Thereof
12 Oct 23
The invention provides α-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor.
Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL, Ernest LOUMAYE, Oliver POHL, Jean-Pierre GOTTELAND
Filed: 10 Nov 22
Utility
Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
19 Sep 23
The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist.
Ernest Loumaye, Jean-Pierre Gotteland, Oliver Pohl
Filed: 5 Jun 18
Utility
Oral Formulations of Pyrrolidine Derivatives
20 Jul 23
The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions.
Andre CHOLLET, Oliver POHL
Filed: 22 Aug 22
Utility
Biomarkers for Oxytocin Receptor Antagonist Therapy
30 Mar 23
The disclosure provides compositions and methods for determining the propensity of a subject (e.g., a female human subject) undergoing embryo transfer therapy to benefit from administration of an oxytocin receptor antagonist, as well as for treating such patients accordingly.
Oliver POHL, Ernest LOUMAYE, Jean-Pierre GOTTELAND
Filed: 9 Feb 21
Utility
Pyrrolidine Derivatives As Oxytocin/vasopressin V1A Receptors Antagonists
30 Mar 23
The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
Andre CHOLLET
Filed: 28 Jan 22
Utility
Compositions and Methods for the Treatment of Estrogen-dependent Disorders
2 Mar 23
The present disclosure provides compositions and methods for treating estrogen-dependent disorders, such as disorders of the female reproductive system, including uterine fibroids and endometriosis, among others.
Jean-Pierre GOTTELAND, Ernest LOUMAYE, Oliver POHL
Filed: 6 Nov 19
Utility
Compositions and methods for delaying the incidence of labor
27 Dec 22
The invention provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks.
Jean-Pierre Gotteland, Oliver Pohl
Filed: 14 May 19
Utility
Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
13 Dec 22
The invention provides α-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor.
Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel, Ernest Loumaye, Oliver Pohl, Jean-Pierre Gotteland
Filed: 27 Jan 20
Utility
Oxytocin Antagonist Dosing Regimens for Promoting Embryo Implantation and Preventing Miscarriage
13 Oct 22
Ernest LOUMAYE, Oliver POHL, Jean-Pierre GOTTELAND
Filed: 31 Aug 20
Utility
Compositions and Methods for the Treatment of Estrogen-dependent Disorders
29 Sep 22
The present disclosure provides compositions and methods for treating estrogen-dependent disorders, such as disorders of the female reproductive system, including uterine fibroids and endometriosis, among others.
Jean-Pierre GOTTELAND, Elke BESTEL
Filed: 7 Aug 20
Utility
GNRH Antagonists for the Treatment of Estrogen-dependent Disorders
15 Sep 22
The present disclosure provides compositions and methods for treating estrogen-dependent disorders, such as disorders of the female reproductive system, including uterine fibroids and endometriosis, among others.
Jean-Pierre GOTTELAND, Elke BESTEL
Filed: 7 Aug 20
Utility
Oral formulations of pyrrolidine derivatives
23 Aug 22
The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions.
Andre Chollet, Oliver Pohl
Filed: 12 Sep 19
Utility
Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists
26 Apr 22
The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
Andre Chollet
Filed: 26 Mar 20
Utility
Compositions and Methods for the Treatment of Adenomyosis and Rectovaginal Endometriosis
21 Apr 22
The present disclosure provides compositions and methods for treating endometrial growth disorders in a patient, such as a human patient, and particularly pre-menopausal female human patients.
Jean-Pierre GOTTELAND, Ernest LOUMAYE
Filed: 29 Oct 19
Utility
Pyrrolidine Derivatives As Oxytocin/vasopressin V1A Receptors Antagonists
18 Feb 21
The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
Andre CHOLLET
Filed: 26 Mar 20
Utility
Oral Formulations of Pyrrolidine Derivatives
9 Sep 20
The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions.
Andre CHOLLET, Oliver POHL
Filed: 11 Sep 19
Utility
Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same
24 Aug 20
Crystalline (3Z,S3)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed.
André Chollet
Filed: 24 May 17
Utility
Gonadotropin-releasing Hormone Antagonist Dosing Regimens for Treating Uterine Fibroids and Reducing Menstrual Blood Loss
10 Jun 20
The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist.
Ernest LOUMAYE, Jean-Pierre GOTTELAND, Oliver POHL
Filed: 4 Jun 18
Utility
Alpha-amino Esters of Hydroxypropylthiazolidine Carboxamide Derivative and Salt Form, Crystal Polymorph Thereof
20 May 20
The invention provides α-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1′-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor.
Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL, Ernest LOUMAYE, Oliver POHL, Jean-Pierre GOTTELAND
Filed: 26 Jan 20
Utility
Gonadotropin-releasing Hormone Antagonist Dosing Regimens for the Treatment of Endometriosis
6 May 20
The invention provides methods of treating endometriosis in a patient by administration of a gonadotropin-releasing hormone (GnRH) antagonist, for instance, according to dosing regimens predicated on the patient's level of anti-Müllerian hormone (AMH) or β17-estradiol (E2).
Ernest LOUMAYE, Jean-Pierre GOTTELAND
Filed: 4 Jun 18